Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • THC Global (THC) has completed the first farm-to-pharma processing of medicinal cannabis at its Southport Manufacturing Facility
  • This is a major milestone for the company as it is now well-positioned to market its products domestically and internationally
  • Initially, products supplied to Australian patients will come under the ‘Canndeo’ brand
  • In addition, THC confirmed it has been granted import and export licences from the Australian Office of Drug Control
  • THC Global is up 8.11 per cent and shares are trading for 40 cents each

THC Global (THC) has completed the first farm-to-pharma processing of medicinal cannabis at the Southport Manufacturing Facility.

This facility is the largest pharmaceutical bio-floral extraction facility in the Southern Hemisphere that is licensed and to process medicinal cannabis.

Initial production marks a significant milestone for, not only THC, but also the Australian medicinal cannabis industry.

It seems the company has been moving relatively quickly as it was only granted the last two licences required to produce and distribute product in late October.

CEO Ken Charteris
Image sourced from THC Global

“THC Global’s medicinal cannabis team have achieved a major milestone today both for the Company and for the Australian medicinal cannabis industry by producing our first farm-to-pharma medicinal cannabis at our Southport Facility, in advance of our commercial-scale launch next year,” CEO Ken Charteris said.

The company’s ‘Canndeo’ brand will be used to globally market its Australian cannabis medicines. An initial launch of the Schedule 4 CBD oral liquid medicine, followed by additional CBD-THC products later next year.

The large scale production capacity THC Global has will enable the supply of medicinal cannabis products to Australian patients.

“THC Global has ready-to-go production assets within Australia capable of servicing over 250,000 patients in addition to the global export market, making THC Global a leader in the Australian medicinal cannabis industry, and in prime position to be a global exporter of Australian medicinal cannabis medicines,” Ken added.

THC is now well-positioned to significantly benefit from the future of medicinal cannabis domestically and internationally.

The pharmaceutical company has also confirmed being granted import and export licences from the Australian Office of Drug Control. These licences allow THC to import cannabis at Southport and for the export from the relevant facility.

THC Global is up 8.11 per cent and shares are trading for 40 cents each at 11:38 am AEDT.

THC by the numbers
More From The Market Herald
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito

" Botanix Pharmaceuticals (ASX:BOT) progresses clinical programs

Botanix Pharmaceuticals (BOT) progressed a number of clinical programs during the September quarter.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham

" Recce Pharmaceuticals (ASX:RCE) receives ethics approval to begin R327 trial

Recce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin its phase one intravenous (IV) trial of RECCE327 (R327).
Noxopharm (ASX:NOX) - CEO, Dr Graham Kelly

" Noxopharm (ASX:NOX) granted Australian and European patents

Noxopharm (NOX) has been granted Australian and European patents for its use of Veyonda to achieve safer chemotherapy.

" ACCC granted injunction to block Virtus Health’s (ASX:VRT) purchase of IVF clinics

Australia’s Federal Court has granted the ACCC an interlocutory injunction to temporarily stop Virtus Health (VRT) from acquiring a string of fertility clinics.